Deutsche Bank Maintains Buy on Sutro Biopharma, Raises Price Target to $55

Benzinga Newsdesk www.benzinga.com Positive 85.6%

Neg 0% Neu 0% Pos 85.6%

Deutsche Bank analyst James Shin maintains Sutro Biopharma (NASDAQ:STRO) with a Buy and raises the price target from $51 to $55.